Go Pro
→ ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I. (From Brownstone Research) (Ad)tc pixel
NASDAQ:CALC

CalciMedica Q2 2024 Earnings Report

CalciMedica logo
$0.82 -0.11 (-12.06%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$0.83 +0.01 (+1.74%)
As of 07:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

CalciMedica EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Announcement Details

Quarter
Q2 2024
Date
8/12/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CalciMedica's next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules.

Conference Call Resources

CalciMedica Earnings Headlines

CalciMedica, Inc.: CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
June 25, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68852934-calcimedica-inc-calcimedica-announces-clinical-development-of-auxora-may-proceed-following-fda-review-of-kourage-trial-interim-safety-data-008.htm
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC)
June 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/351/analysts-offer-insights-on-healthcare-companies-onkure-therapeutics-okur-and-calcimedica-calc/
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel
July 14 at 1:00 AM  |  Brownstone Research (Ad)
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
June 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/calcimedica-announces-private-placement-financing-for-up-to-approximately-49-million-to-advance-pulmonary-hypertension-program-302808596.html
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
June 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/calcimedica-announces-clinical-development-of-auxora-may-proceed-following-fda-review-of-kourage-trial-interim-safety-data-302808584.html
CalciMedica Inc Ordinary Shares CALC
May 19, 2026  |  morningstar.comM
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC), Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients.

CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.

View CalciMedica Profile
Earnings Tools